Probenecid as Medication for Alcohol Use Disorder

• Status: Recruiting
• Trial end date: 2022-02-22
• Target enrollment: 0
• Participant gender: All

Summary

The design is a randomized, within-subject, crossover, double-blind, placebo-controlled human alcohol laboratory study with one oral dose of 2g probenecid or placebo administered in two laboratory sessions.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Brown University
• Treatments: Probenecid

Criteria

Inclusion Criteria:

• Male or female, 21-70 (inclusive) years; women >7 drinks/week; men >14 drinks/week;

• meet any DSM-5 criteria score for AUD;

• Breath alcohol Content (BrAC)=0.00 at each visit;

• In good health as confirmed by medical history, physical examination and lab tests;

• Willing to adhere to the study procedures;

• Understand informed consent and questionnaires in English at an 8th grade level

Exclusion Criteria:

• Women who are breastfeeding or have a positive urine screen for pregnancy

• CrCl < 60mL/min

• Taking aspirin (salicylates may reduce effect of probenecid)

• Taking penicillin

• Taking methotrexate (may increase concentration)

• Taking other medications that may interact with probenecid

• History of suicide attempts in the last three years

• Current diagnosis of another substance disorder(s) other than nicotine, as assessed by self-reports and urine toxicology screen at baseline

• History of hypersensitivity to sulfa drugs